左心房黏液瘤术后新发房性心律失常导管消融的安全性与有效性
回顾性纳入9例左心房黏液瘤外科术后新发房性心律失常并接受导管消融的患者,年龄(55.8±9.1)岁,男性3例,阵发性房颤3例、房扑或房速6例。所有患者消融成功且无围术期严重并发症,随访40.0(27.5,55.5)个月,6例维持窦性心律,总体维持比例为2/3,无黏液瘤复发及死亡等事件。
要点
- 左心房黏液瘤术后新发房性心律失常患者行导管消融安全,围术期无严重并发症。
- 初次消融后随访40.0个月,9例中6例维持窦性心律,总体维持比例2/3。
- 复发患者可考虑再次消融,本组3例复发中2例再消融,1例维持窦性心律。
核心结论
- 左心房黏液瘤外科术后新发房性心律失常患者接受导管消融安全、有效,可作为治疗选择。
研究设计与样本
- 回顾性研究,纳入北京安贞医院2014年9月至2019年11月左心房黏液瘤术后新发房性心律失常并接受导管消融的患者9例。
- 收集基线临床数据、消融术中参数和围术期严重不良事件,随访心律失常复发和临床预后,采用Kaplan-Meier生存曲线分析窦性心律维持率。
主要发现
- 9例患者年龄(55.8±9.1)岁,男性3例(3/9),阵发性房颤3例(3/9),房扑或房速6例(6/9)。
- 所有患者均成功完成导管消融,围术期未发生卒中、心包积液、心脏压塞、血管并发症及大出血事件。
- 随访40.0(27.5,55.5)个月,6例(6/9)初次消融后维持窦性心律,总体窦性心律维持比例为2/3。
- 3例房颤患者中1例(1/3)术后3个月出现早期房颤复发;6例房扑或房速患者中2例(2/6)分别于术后19、29个月出现极晚期新发房颤和/或复发房扑。
- 3例复发患者中2例接受再次消融,其中1例维持窦性心律;随访期间无黏液瘤复发、死亡、卒中、急性心肌梗死等事件。
临床怎么用
- 对于左心房黏液瘤外科术后新发房性心律失常患者,导管消融可作为安全、可行的治疗选择。
- 术后需长期随访心律失常复发,本组复发时间可延迟至术后29个月。
- 复发患者可考虑再次导管消融,本组再消融后部分患者可维持窦性心律。
局限性
- 本研究为单中心回顾性研究,样本量仅9例,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the safety and efficacy of catheter ablation in patients with new-onset atrial arrhythmia after surgical excision of left atrial myxoma. Methods: Nine patients with new onset atrial arrhythmia and a prior history of left atrial myxoma, who received surgical myxoma excision and catheter ablation between September 2014 and November 2019, were included in the present study. Baseline characteristics, procedural parameters during catheter ablation, severe perioperative adverse events, recurrence rate of arrhythmia and clinical prognosis were analyzed. Kaplan Meier survival analysis was used to define the maintenance rate of sinus rhythm after catheter ablation in this patient cohort. Results: Nine patients were included. The average age was (55.8 ± 9.1) years old (3 male), there were 3 patients (3/9) with paroxysmal atrial fibrillation (PAF) and 6 patients (6/9) with atrial flutter or atrial tachycardia (AFL or AT). Ablation was successful in all patients, there were no perioperative complications such as stroke, pericardial effusion, cardiac tamponade, vascular complications or massive hemorrhage. During a mean follow-up time of 40.0 (27.5, 55.5) months, sinus rhythm was maintained in six patients (6/9) after the initial catheter ablation. The overall sinus rhythm maintenance rate was 2/3. In addition, 1 out of the 3 AF patients (1/3) developed recurrence of AF at 3 month after ablation, and 2 out of the 6 AFL or AT patients (2/6) developed late recurrence of AF or AFL (19 months and 29 months after ablation), two out of three patients with recurrent AFs or AFL received repeated catheter ablation and one patient remained sinus rhythm post repeat ablation. Meanwhile, there was no recurrence of atrial myxoma, no death, stroke, acute myocardial infarction and other events during the entire follow-up period. Conclusions: Catheter ablation is a safe and feasible therapeutic option for patients with new-onset atrial arrhythmia after surgical excision of left atrial myxoma. 目的: 初步探讨左心房黏液瘤外科术后新发房性心律失常的患者接受导管消融的安全性与有效性。 方法: 回顾性选取北京安贞医院2014年9月至2019年11月左心房黏液瘤术后新发房性心律失常并接受导管消融治疗的患者9例。收集患者的基线临床数据、消融术中参数和围术期严重不良事件,并随访导管消融术后心律失常复发情况和临床预后,采用Kaplan-Meier生存曲线分析导管消融术后窦性心律维持率。 结果: 9例患者年龄(55.8±9.1)岁,男性3例(3/9),阵发性心房颤动(房颤)3例(3/9),心房扑动(房扑)或房性心动过速(房速)6例(6/9)。所有患者均成功完成导管消融治疗,围术期均未发生卒中、心包积液、心脏压塞、血管并发症及大出血事件。随访40.0(27.5,55.5)个月,9例患者中有6例(6/9)初次消融术后维持窦性心律,总体窦性心律维持比例为2/3。3例房颤患者中有1例(1/3)出现早期房颤复发(术后3个月),6例房速或房扑患者中有2例(2/6)房扑患者出现极晚期新发房颤和/或复发房扑(分别为术后19、29个月)。3例复发患者中有2例接受再次消融,其中1例维持窦性心律。所有患者随访期间未复发黏液瘤,未发生死亡、卒中、急性心肌梗死等事件。 结论: 左心房黏液瘤外科术后新发房性心律失常患者接受导管消融安全、有效,可以作为一项治疗选择。.
引用
- Zhao X, Su X, Long DY, et al. [Efficacy and safety of catheter ablation in patients with new-onset atrial arrhythmia after surgical excision of left atrial myxoma]. Zhonghua Xin Xue Guan Bing Za Zhi. 2021. PMID: 33429488. doi:10.3760/cma.j.cn112148-20200407-00286
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。